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Abstract
A 56-kDa protein isolated from the mucus of the
European sea hare Aplysia punctata shows a prefer-
ential toxicity to autonomously growing transformed
mammalian cells. Cell death induced by this protein
differs from both apoptosis and necrosis. The cytotoxic
effects are irreversible and become apparent at nano-
molar concentrations in a cell type–dependent manner.
In contrast, injection of micromolar concentrations into
mice is tolerated without apparent negative consequen-
ces. Microsequencing of the 56-kDa protein released a
peptide sequence whose corresponding nucleotide
sequence was used as probe to screen A. punctata
RNA-based cDNA and to select cDNA clones encoding
polypeptides comprising the target peptide. Two closely
related cDNA were detected. The cDNA encoding a
polypeptide 558 aa in length was considered to reflect a
bona fide clone encoding the cytotoxic protein. Its
protein-coding section was recloned in vectors suitable
for expression in Escherichia coli, in mammalian cells,
and in insect cells, respectively. The E. coli–expressed
polypeptide was biologically inactive. Transfectedmam-
malian cells expressed a cytotoxic factor and died
thereof as if treated with the genuine cytotoxic protein.
In contrast, transfected insect cells, which proved to be
much less sensitive when treated with the genuine
protein, expressed the cytotoxic factor and continued to
proliferate, allowing to establish stable insect cell lines
expressing sufficient amounts of the cytotoxic factor for
further characterization.
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Introduction
Marine organisms represent an essentially unexploited
reservoir for genes and metabolic products of potential
biological and/or pharmacological interest [1–3] . So far,
literature on natural products derived from marine organisms
is dominated by low-molecular -weight compounds charac-
terized by cytotoxicity. A number of such natural drugs are
either clinically applied or under evaluation as potential
anticancer drugs [1–3] . In contrast, reports on exploitable
genes from marine organisms and their products are rare.
The green fluorescent protein from the jellyfish Aequorea
victoria may serve as an example for a gene of basic
biological interest, which is widely used in biotechnology as
reporter for studies on gene expression and protein local-
ization in living cells [4 ] . The latter technology is also applied
in the present study.
Sea hares appear to represent another species producing
high-molecular -weight gene products of interest. Originally,
the toxicity of the mollusc Aplysia was found to be due to low-
molecular-weight metabolic substances deriving from algal
diet [5 ] . However, cytolytic, antimicrobial, and antifungal
activities could be detected in biochemical isolates of high
molecular weight from the sea hares Aplysia kurodai,
A. juliana, and Dolabella auricularia. Accordingly, it was
suggested that these organismsmight produce water -soluble
gene-expressed biopolymers of pharmacological interest
[5,6] . Furthermore, these biochemical investigations suggest
that sea hares produce a number of closely related
glycoproteins of different sizes and with different biological
activities. First attempts to characterize these proteins on
the sequence level led to the molecular cloning of one
A. kurodai–derived cDNA, which showed significant
sequence identities with the cDNA encoding a protein
produced by the giant African snail Achatina fulica [7 ] .
However, a clear correlation of the protein encoded by the
cloned A. kurodai cDNA with any biological activity is missing.
This is most likely due to the fact that the biologically active
molecules are glycoproteins and that recombinant expres-
sion in Escherichia coli results in biologically inactive
proteins.
The potential pharmacological value of Aplysia -derived
proteins stimulated our approach to identify cytotoxic
activities of the European sea hare A. punctata on the
sequence level. A bioassay-guided fractionation of the
secreted mucus of albumen glands released a 56-kDa
glycoprotein, which showed cytotoxic effects on autono-
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mously growing cells in nanomolar concentrations. Based on
its cytotoxicity, its possible effects on neoplasia, and its origin
Aplysia, the protein was termed cyplasin. Microsequencing
released an internal peptide whose corresponding nucleo-
tide sequence was used as probe for the molecular cloning of
two cDNA encoding closely related A. punctata proteins. A
cytotoxic recombinant form of one of these variants is
expressed in mammalian and in insect cells underlining the
validity of the cloning approach and providing the basis for a
potential application of this bioactive molecule.
Materials and Methods
Biochemical Isolation of Cyplasin
Mucus of albumen glands of the sea hare A. punctata can
be obtained from animals during the spawning season when
they come to the shore (around April on Ile d’Yeu) . By gently
squeezing the animal, the mucus (approximately 2.5 ml) is
excreted as purple fluid, forming a gel when exposed to air. It
is immediately diluted (1:1, vol /vol ) with phosphate-
buffered saline (PBS; 150 mM NaCl, 10 mM NaH2PO4, pH
7.2) and placed at 48C. After 2 to 3 hours, the mixture
becomes completely soluble. This step is followed by
centrifugation at 10,000g, 15 minutes, 48C, to remove
debris. The supernatant can be frozen and kept at 808C
without loss of activity. For further purification, the mucus is
dialysed against 1000 vol of 50 mM MOPS, 1 mM
dithioerythreitol, 0.5 mM EDTA, 5 mM KCl, pH 7.2 for
24 hours at 48C. Protein fractions containing the cytotoxic
activity were isolated by fractionated precipitation with
ammonium sulphate. Cytotoxic activity was detected in
precipitates collected between 33%/50% (pellet 1) and
50%/66% (pellet 2) saturation, respectively. Most of the
cytotoxic activities were usually found in pellet 1. For
cytotoxicity tests, pellets were dissolved in 300 l of PBS,
dialysed against the buffer described above. The most active
fractions comprised protein(s) migrating as an essentially
single band on a sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gel (Figure 1 ) .
Identification of the SGDYILIASYAD Peptide in the Fraction
of Cytotoxic Protein(s)
Material used for the microsequencing procedure was
further purified by gel filtration (G-200 column; Sigma-
Aldrich, Taufkirchen, Germany) in a buffer comprising
50 mM MOPS, 1 mM dithioerythreitol, 0.5 mM EDTA, 5 mM
KCl, at pH 7.2. The dialyzed and lyophilized efflux was
submitted to SDS-PAGE and blotted to a PVDF membrane
(ProtoBlot; Applied Biosystems, Weiterstadt, Germany) .
Sections containing the region of interest were analysed by
microsequencing procedures performed by WITA (Berlin,
Germany) .
Cytotoxicity Test
Aliquots from each pellet, dissolved in 300 l of PBS,
were tested for their toxic effects on autonomously growing
cells. The term ‘‘autonomously growing cells’’ is used for all
cells capable of proliferating in vitro, in contrast to cells
proliferating within an organism. Routine tests were per-
formed using the kangaroo rat cell line PtK2 and the human
cell line HeLa. 4104 cells were seeded in 24-well plates
containing 500 l of medium per well resulting in about 50%
confluency after 24 hours. At this time, undiluted aliquots of
the redissolved pellet (s) (5 l ) were added and cell cultures
in parallel wells were supplemented with aliquots (5 l ) of
serial dilutions.
Characterization of Cell Death Induced by Genuine Cyplasin
Morphological alterations of cells undergoing cyplasin-
induced death were recorded by light microscopy. In
addition, permeability changes of the plasma membranes
were investigated by incubating the cyplasin- treated cells
with the nonmembrane permeant compound H33257
(Sigma-Aldrich) , 0.5 g/ml, or propidium iodide (Boeh-
ringer Ingelheim, Ingelheim, Germany) , 1 g/ml. Staining of
nuclei was considered as indication for pathological perme-
ability changes associated with necrosis or the final stages of
apoptosis. For the visualization of the actin cytoskeleton,
cells were treated with cyplasin in cell medium at 378C for the
times indicated, washed in prewarmed PBS, and fixed in
ice-cold ethanol at 188C for 10 minutes on ice. After
several washes with PBS, cells were treated for 10 minutes
in 0.5% bovine serum albumin (BSA) in order to reduce
unspecific staining and incubated in FITC–phalloidin
(Molecular Probes, Leiden, the Netherlands) , diluted 1:300
in 0.5% BSA/PBS, for 45 minutes at room temperature. The
unbound phalloidin was removed by several washes with
PBS and the cells were viewed in a fluorescence microscope
using the appropriate filters (ZEISS Axiovert 405) . To
differentiate the apoptotic form of death, cyplasin- treated
cells were incubated in 5 g/ml FITC- labeled Annexin V
(Boehringer Ingelheim) for 20 minutes in Ca2+ -containing
Figure 1. SDS-PAGE of cyplasin isolated by a bioassay -guided fractionation
of the secreted mucus of A. punctata. The figure shows a 12% SDS
polyacrylamide gel loaded with the most active fraction ( lane cyplasin ) . The
proteinaceous material migrates with an apparent molecular mass of 56 kDa.
Lane M is loaded with marker proteins.
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buffer and the presence of a potential phosphatidyl serine–
Annexin complex was evaluated by fluorescencemicroscopy
using appropriate filters [8 ] . For control, apoptosis was
induced in cells by incubation with 0.2 g/ml staurosporine
for 3 hours. This treatment induced a clear translocation of
phosphatidylserine to the outer face of the plasma mem-
brane, thus becoming accessible to the FITC–Annexin [9 ] ;
the concentration of staurosporine, however, was sufficiently
low to prevent the parallel staining of cell nuclei with
propidium iodide.
A. punctata cDNA
Total RNA was isolated from albumen glands of the sea
hare A. punctata by means of the Qiagen RNA isolation kit.
The Clontech SMART II polymerase chain reaction (PCR)
cDNA synthesis kit (K1052-1, Clontech, Heidelberg, Ger-
many) was used to convert 100 ng amounts of total RNA into
cDNA. First strand synthesis was primed with the modified
oligo-dT included in the kit and primer extension was
performed with the recommended RNase H point mutant
reverse transcriptase (Superscript II; Invitrogen, Groningen,
the Netherlands) . The SMART II oligo inducing the template
switch at 50 ends was included in the first strand reaction.
These reactions and PCR amplifications of first strand cDNA
by means of the modified oligo (dT) and SMART II primers
were performed according to the instructions of the producer
of the kit.
Molecular Cloning of cDNA Encoding Proteins Comprising
the Peptide SGDYILIASYAD
Amplified cDNA was used as a template and PCR
reactions were primed with combinations of specific primers
corresponding to the search sequence and with nonspecific
primers, e.g., modified oligo-dT and SMART II, respectively.
Amplification products was recloned in a pBluescript -derived
T-overhang vector and sequenced. The validity of these
sequences was verified by PCR reactions primed with oligo
deoxynucleotides corresponding to sequences upstream
and downstream of the specific SGDYILIASYAD-encoding
primer. These probe- independent products contained the
nucleotide sequence encoding the peptide SGDYILIASYAD.
Sequences found upstream of SGDYILIASYAD-encoding
sequence were unique, except for several base exchanges
discussed in the text. In contrast, two 30 end sequences
differing in length could be detected (L and S).
Fusion and Expression Constructs
The protein-coding sections were PCR-amplified with
primers placing suitable restriction sites to the 50 and 30
ends of the amplification products. Following digestion
with the corresponding restriction endonucleases, the
products were either directly cloned into the expression
vectors pcDNA3 (Invitrogen; for expression in mammalian
cells ) , pQE30 (Qiagen, Hilden, Germany; for expression
in E. coli ) , pIZ/V5-His ( Invitrogen; for expression in insect
cells ) , or fused with the EGFP-encoding cDNA (Clontech)
prepared in the XhoI /NotI sites of the pBluescript vector.
Excision of the EGFP-tagged fragments and recloning in
appropriate sites of the pcDNA3 vector or the pIZ/V5-His
vector resulted in the corresponding cyplasin–EGFP
expression constructs suitable for expression of fluores-
cently labeled fusion proteins in mammalian and insect cells,
respectively.
Transfections and Recombinant Protein Expression
E. coli M15 cells were transformed with the pQE30
plasmids containing the cyplasin-L– and cyplasin-S–
encoding inserts in frame with the His tag of the vector.
The expressed His- tagged proteins were isolated by means
of Ni–NTA agarose according to the protocol supplied by
Qiagen.
Mammalian cells were transfected with the pcDNA3
plasmids containing either EGFP-tagged or nontagged
cyplasin-L– and cyplasin-S–encoding inserts by means
of the Effectene transfection kit (Qiagen) . Cells transfected
with constructs containing the insert encoding cyplasin-L–
EGFP or cyplasin-L–EGFP could not survive longer
periods. However, supernatants of such cultures contained
the cytotoxic factor described in the text.
SF9 cells were transfected with the pIZ/V5-His plasmids
containing either EGFP-tagged or nontagged cyplasin-L–
encoding inserts using, in addition, the Effectene trans-
fection kit (Qiagen) . In contrast to mammalian cells,
transfected insect cells survived. Expression was followed
either by fluorescence microscopy of living cells or by
testing of cytosolic extracts for the presence of a cytotoxic
factor.
Stably Transfected SF9 Cells for Large-Scale Production of
Cyplasin-L–EGFP
SF9 cells transfected with the plasmid pIZ/V5-His–
cyplasin-L–EGFP were grown for 3 months as semi-
attached cells at 268C in TNM-FH insect medium (Appli-
chem, Darmstadt, Germany) supplemented with 10% fetal
calf serum, 5 mM Glutamax (Life Technologies, Karlsruhe,
Germany) , and 100 g/ml zeocin ( Invitrogen) . The cell
cultures were diluted 1:3 at 4-day intervals. The original
transfection efficiency was approximately 10%; after a
3-month period, 5% of the cells remained fluorescent. The
latter fraction was considered to be stably transfected. Cells
of this fraction were separated by means of a fluorescence-
activated cell sorter (Becton-Dickinson, Heidelberg, Ger-
many) . Following a second sorting performed after 4 weeks,
the resulting culture could be grown in spinner cultures up to
several litres and more than 90% of these cells expressed
cyplasin-L–EGFP fusion protein.
Recovery of the Cytotoxic Factor from SF9 Cells Stably
Expressing Cyplasin-L–EGFP
The EGFP-tagged cyplasin-L is not secreted into the
medium of SF9. Routinely, 1 to 2108 stably transfected SF9
cells were washed by suspension and centrifugation
(1000g, 3 minutes) , once in PBS, and once in 50 mM
MES, 1 mM EDTA, 5 mM KCl, 0.1% mercaptoethanol, pH
6.0. They were homogenized in 5 ml of the latter buffer.
Homogenization and all subsequent steps were performed at
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48C. A protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany) was present throughout the purifica-
tion procedure. The homogenate was centrifuged (100,000
g, 60 minutes) , and the supernatant was applied to a DEAE
Cellulose column (DE52; Sigma-Aldrich) that had been
equilibrated with the buffer described above. The column
was washed extensively with the buffer used for equilibration
followed by application of a NaCl gradient (0 to 200 mM).
Eluted fractions were tested for the presence of the cytotoxic
factor by addition of 100 l of each fraction to indicator cells
(PtK) growing in 500 l of culture medium. If present,
cytotoxic effects were observed after about 5 hours. Factor -
containing fractions were eluted between 60 and 80 mM
NaCl. Fractions with these characteristics were considered
as ‘‘standard’’ extracts, and used for other biological tests.
Identification of Cyplasin-L–EGFP in Cytotoxic Extracts
Isolated from Stably Transfected SF9 Cells
Protein fractions isolated as described above and
exhibiting cytotoxic activity were concentrated and sepa-
rated by 12.5% SDS-PAGE. Two identical samples ( includ-
ing a protein standard) were separated on the same gel.
One section of the gel was stained using a silver -staining
procedure; the other section was electroblotted (semidry
blotting apparatus; Biometra, Go¨ttingen, Germany) to a
PVDF transfer membrane (Westran, Schleicher, and
Schuell, Dassel, Germany) . Buffer composition was 3.03 g
of boric acid, 200 ml of methanol, 800 ml of H2O, pH 9.0.
Following blocking with BLOTTO [10] , the membrane was
incubated for 3 hours (268C) with anti -GFP antibody
(ABCAM, Cambridge, UK) diluted 1:2000 in PBS, pH 7.2,
containing 0.1% BSA. After prolonged rinsing in PBS,
immunodetection was performed by means of an alkaline
phosphatase–coupled goat–antirabbit antibody (Dianova,
Hamburg, Germany) , which was applied for 3 hours at 268C,
diluted 1:12000 PBS, pH 7.2, containing 0.1% BSA. The blot
was rinsed in PBS and placed into the staining solution
consisting of 100 mM TRIS, 5 mM MgCl2, 0.3 mg/ml nitro
blue tetrazolium, 0.15 mg/ml 5-bromo-4-chloro-3- indolyl-
phospate, pH 9.5.
Animal Experiments
DBA2 mice were injected with 300 l (10 M) of genuine
cyplasin, either in the tail vein (group 1) or subcutaneously
(group 2) . Cyplasin had been dialysed before against a large
volume of PBS for 24 hours at 48C and tested for positive
cytotoxicity immediately before injection by incubating PtK
cells with 10 nM cyplasin. Recombinant cyplasin was also
dialysed against PBS, tested for positive cytotoxicity before
injection, and 300 l was injected into the tail vein. Mice were
maintained under standard conditions and observed for
4 weeks.
Other Methods
Database searches and sequence analyses were per-
formed by means of the HUSAR program package (DKFZ)
that is a collection of sequence analysis tools based on the
GCG program package developed by GCG. For the
identification of the secretory signal sequence, we applied
the McGeoch scan program [11] . DNA sequencing was
performed by A. Hunziker (German Cancer Research
Center) by means of an automatic DNA sequencer, model
373A (Applied Biosystems).
Results
Molecular Cloning of Cyplasin-Encoding cDNA
cDNA prepared from total RNA of the albumen gland of
A. punctata comprises more than one transcript encoding the
peptide SGDYILIASYAD. Two cDNA were cloned encoding
proteins, which diverge significantly in their carboxy- terminal
sections but which comprise the target sequence (Figure 2 ) .
One of these cDNA encodes a protein of 558 aa residues
with a molecular mass of 62.4 kDa (termed cyplasin-L) ,
whereas another cDNA reflects a transcript encoding a
shorter protein (421 aa residues, molecular mass 46.9 kDa,
termed cyplasin-S) . Moreover, PCR on total cDNA with
cyplasin-L–specific primer pairs results in DNA fragments
whose sequences diverge from those encoding cyplasin-L
and cyplasin-S, respectively. Accordingly, mRNA appear to
exist, which are neither identical with cyplasin-L nor with
cyplasin-S. These sequence microheterogeneities suggest
that A. punctata produces an unknown number of very
similar, but not 100%, identical proteins that comprise the
target sequence. On the basis of the available data, it cannot
be decided whether these different mRNA and proteins
derive from one single gene, e.g., by alternative splicing in
combination with RNA editing, or whether there exists a
cluster of very similar, but not 100%, identical genes.
Sequence Characteristics of the Proteins Cyplasin-L and
Cyplasin-S Encoded by the Cloned cDNA
Biochemical data suggest (not shown) that the naturally
occurring cyplasin is a glycoprotein. The cyplasin-L cDNA-
derived amino acid sequence comprises five Asn- linked
(N-X-S or N-X-T) glycosylation sites at positions N-151,
N-271, N-401, N-416, and N-422 that is in agreement with
the biochemical data. The glycosylation sites 1 to 4 are
unchanged in the polypeptide derived from the cyplasin-S
cDNA, whereas the position N-422 is missing in the shorter
sequence.
The N-termini start with a hydrophobic secretory signal
sequence of high probability and a predicted cleavage site
between aa residues 52 (Ser) and 53 (Ala) . Accordingly,
the molecular masses of the mature and expectedly func-
tional proteins amount to 57.2 and 41.6 kDa, respectively.
The calculated isoelectric points of these mature proteins are
5.54 (charge 13) for cyplasin-L and 6.20 (charge 5) for
cyplasin-S.
Database searches with the nucleotide sequence
released similarities with two other Aplysia sequences,
namely A. kurodai albumen gland mRNA for aplysianin-A
precursor (70.9% identities, D83255 [12] ) , and Ac.
fulica Ferussac mRNA for achacin (52.2% identities,
X64584 [7] ) .
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Database searches with cyplasin subsequences released
the amino acid sequences of the Aplysia species mentioned
above and a number of protein sequences with longer
strings of local identities or homologies. All the latter
sequences belong to the class of monoamine oxidases.
Table 1 shows alignments of one prominent cyplasin
peptide string with subsequences of eukaryotic and
prokaryotic monoamine oxidases. The significance of this
finding remains to be elucidated; however, it is of interest to
note that database searches with this and other cyplasin-
typical strings released no significant hits with proteins from
other classes.
Expression of Biologically Inactive Recombinants in E. coli
Recombinant expression of cyplasin-encoding cDNA
sequences in the pQE/E. coli M15 system results in
polypeptides, which are completely insoluble in buffers
containing no detergents, and suspensions of such recom-
binantly expressed polypeptides could not exert any cyto-
toxic effect when incubated together with cultured cells (not
shown). This missing cytotoxic activity is suggestively due to
incorrect folding and/or the absence of posttranslational
modifications of the polypeptides expressed in the E. coli
system.
Generation of Bioactive Recombinants in Mammalian Cells
In contrast, mammalian cells, e.g., HeLa S3 suspension
cells, produce a cytotoxic factor when transfected with
CMV vector-driven expression constructs specifying either
cyplasin-L or EGFP-tagged cyplasin-L. This factor is not
detectable in cultures of nontransfected cells nor in
cultures transfected with constructs expressing the cypla-
sin-S version. The production of the cytotoxic factor is
obvious because all cells of factor -producing cultures
finally die in the typical manner that is observed when
Table 1. Database Searches with the pCyplasin -Derived Amino Acid
Sequence Resulted in a Number of Hits with Sequences Reflecting
Monoamine Oxidases.
Sequence Accession Number Organism
62 NIGVFEFCDRVGGRLFT 78 Cyplasin A. punctata
+ V E DRVGGR FT I51346 Rainbow trout
+ V E +RVGGR+ T OXLA_CROAD Crotalus
N+ V E +RVGGR +T AOFA_BOVIN Bovin
+ + V E D VGGR +T AOFB_RAT Rat
+ + V E DRVGGR +T AOFA_HUMAN Human
N+ V E DRVGGR +T AOFB_HUMAN Human
+ + FE +RVGGR+F+ T08202 Prokaryotic
+FE DR+GGR+ + + T22714 Prokaryotic
+ VFE DRVGGR T AOFH_MYCTU Prokaryotic
+ + +FE + VGGR T TR2M_AGRVI Prokaryotic
+ + V+E DR+GG+L+ + TR2M_AGRRA Prokaryotic
+ + + +E DRVGG+L+ + A20966 Prokaryotic
+ + E R GGR+ T E69899 Prokaryotic
+ + + +E DRVGG+L+ + TR2M_AGRT3 Prokaryotic
+ V E DRVGGR + + PUO_MICRU Prokaryotic
Especially a motif between aa positions 62 and 78 is frequently detected. A
selection of aligned subsequences is displayed in the table below.
Figure 2. Amino acid sequences of precursor proteins derived from A.
punctata cDNA comprising the nucleotide subsequences coding for the
( underscored ) internal peptide SGDYILIASYAD. The upper sequence (558
aa residues ) is derived from the nucleotide sequence of the cDNA encoding
the polypeptide termed cyplasin - L, and the lower sequence (421 aa
residues ) is derived from the nucleotide sequence of the cDNA encoding
the polypeptide termed cyplasin -S. In addition to these clearly distinguishable
transcripts, other mRNA may exist with additional differences. PCR with total
cDNA as template and cyplasin - L–specific primer pairs releases sequences
slightly differing from the cloned cyplasin -L and cyplasin -S encoding cDNA
sequences. Amino acid exchanges detected by the PCR procedure are
indicated in brackets. Asn - linked glycosylation sites are found at aa positions
N -151, N -271, N -401, N -416, and N -422. The putative cleavage point of the
secretory signal sequence is between aa 52 (S ) and aa 53 (A ) .
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mammalian cells are treated with genuine cyplasin isolated
from the mucus of A. punctata. Because only a fraction of
cells in such cultures is transfected, it follows that the
cytotoxic factor must be released from the producer cells
with the consequence of cell death of producer and
nonproducer cells. The release of the cytotoxic factor is
well in agreement with the predicted secretory signal at the
amino terminus of the cDNA-derived amino acid sequence
(Figure 2 ) .
Although this self -destructing system is not suitable to
produce significant amounts of biologically active re-
combinants, it reveals the validity of the cDNA cloning
approach and it indicates that the factor encoded by the
cDNA with the longer insert shows the cyplasin- typical
characteristics.
Recombinant Expression of Bioactive Cyplasin-L and
Cyplasin-L to EGFP in Insect Cells
Insect cells (e.g., SF9) are known to be able to perform
posttranslational modifications similar to mammalian cells.
Because SF9 cells proved to be much less sensitive to
genuine cyplasin preparations (not shown), they are
especially suited to generate recombinant cyplasin in
sufficient amounts for biological tests. Transfection of SF9
cells with pIZ vector -driven constructs specifying the
expression of cyplasin-L or of EGFP-tagged cyplasin-L
could not influence the proliferation rate of SF9 cells.
Moreover, the medium of SF9 cells transfected with the
construct specifying that cyplasin-L contained significant
cytotoxic activity for mammalian cell cultures, which shows
that the secretory signal of cyplasin-L is also functioning in
insect cells.
In contrast, no cytotoxic factor was released from SF9
cells transfected with the construct specifying EGFP-tagged
cyplasin-L. The cyplasin-L–EGFP fusion protein is clearly
expressed in SF9 cells, as shown by EGFP-dependent
fluorescence (Figure 3 ) , but no significant amounts of the
cytotoxic factor can be detected in the spent medium of
spinner cultures. Interestingly, the Western blot shown in
Figure 4 points to the deletion of the signal sequence in the
cyplasin-L section of the fusion protein. This cleavage must
occur in such a way that the truncated fusion protein remains
cytosolic. Alternatively, retrograde translocation from the ER
to the cytosol has to be assumed. Such retrograde trans-
locations have already been observed in other systems
before [13–16] .
However, the cytotoxic activity of the recombinantly
expressed truncated cyplasin-L is maintained when fused
to EGFP. The high-speed supernatant of homogenized
cyplasin-L–EGFP–expressing SF9 cells was found to
contain the factor that is cytotoxic to cultured mammalian
cells. Consequently, stably transfected cyplasin-L–EGFP–
expressing SF9 cell lines were generated by fluorescence-
activated cell sorting, and fractions of the high-speed
supernatants of such cultures contained the cyplasin-L–
EGFP fusion protein (Figure 4 ) and exhibited the biological
activities shown in Figure 5.
Characteristic Features of Cyplasin-Dependent Cytotoxicity
Proliferating mammalian cells exhibit characteristic time-
and concentration-dependent morphological changes when
treated with the biochemically isolated genuine cyplasin from
the mucus of A. punctata (Figure 5 ) . The cytotoxic effects of
Figure 3. Insect cells (SF9 ) transfected with the pIZ vector - driven construct
expressing cyplasin - L–EGFP. The upper panel shows SF9 cells in bright
field and the lower panel shows the identical section in fluorescence mode
(515 nm) . Bar, 10 m.
Figure 4. Enrichment of the recombinant cyplasin -L–EGFP fusion protein in
cytotoxic protein fractions released from SF9 cells. Extracts containing the
cytotoxic factor were prepared from SF9 cells expressing cyplasin - L–EGFP
as described under Materials and Methods section. Identical samples were
separated on a 12% polyacrylamide gel. Polypeptides run on parallel gel
sections, together with a protein size marker, were either visualized by a silver
staining procedure or blotted to a PVDF membrane. The membrane was
probed with an anti -EGFP antibody and immunocomplexes formed were
visualized by means of an alkaline phosphatase–coupled second antibody.
( a ) Shows the protein size marker. ( b ) Shows the prominent polypeptides
present in the extract. ( c ) Shows the antigen detected by the EGFP -specific
antibody.
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the genuine cyplasin become visible, e.g., in PtK cells, in less
than 1 hour at 50 nM. For this cell line, the minimum cytotoxic
cyplasin concentration is in the order of 2 nM; however, at
this concentration, the cytotoxic effects appear foremost
after 24 hours. Once induced, the cyplasin effect is
irreversible and cell death is observed even if cyplasin-
containing medium is replaced by fresh medium. Other
cultured mammalian cells show lower (human skin fibro-
blasts, HSF) or even higher sensitivity (human melanoma
cells, glia cells ) (Figure 6 ) .
The morphology of cyplasin- induced cell death is
specific. The cells detach from the substratum, they shrink
and disjoin from each other if grown as monolayer or in
clusters, and occasionally they exhibit numerous small
plasma vacuoles. Morphological changes of this type can
also be observed in cells undergoing apoptotic cell death;
however, typical indicators for apoptosis including nuclear
fragmentation and exposure of phosphatidylserine on the
outer membrane are missing (Figure 7 ) . Similar forms of cell
death have been described by Sperandio et al. [17] and
were termed paraptosis.
Cyplasin exerts its cytotoxic effects only on cells in
interphase. Mitotic cells are still able to complete ana-
phase and cytokinesis at a time when most interphase
cells in the same culture already show the cyplasin- typical
change in morphology (Figure 8 ) . However, following
completion of mitosis, these cells also die when reentering
the interphase. Neither cell permeability nor the micro-
tubular cytoskeleton nor intracellular Ca2+ levels are
affected by cyplasin (not shown). Actin fibers, on the
other hand, react very sensitively to cyplasin. First signs of
depolymerization appear already after 10 minutes; most of
the actin cytoskeleton has disappeared after 30 minutes
(Figure 9b ) with few tangles of fibrous actin remaining
around the nucleus (cf. Figure 9c ) . After a longer
incubation of these cells with cyplasin, no more fibrous
Figure 5. Cytotoxic effects of genuine and recombinant cyplasin -L–EGFP. Four different cell lines were treated for 5 hours with genuine cyplasin and with standard
extracts ( see Materials and Methods section ) from SF9 cells stably expressing cyplasin - L–EGFP. Genuine cyplasin: Primary HSFs, incubated with 50 nM
cyplasin. At this concentration, HSF cells show a slight but typical reaction that implies retraction of the cell membrane and partial detachment. Cell death is not
observed at this concentration. The cells recover and continue to proliferate. Primary human melanoma cells derived from biopsies are more susceptible to the
cytotoxic effect of cyplasin than HSF cells. After addition of cyplasin ( 2 nM ) , the cells show the typical cyplasin - induced membrane changes and finally die
( arrows ) . Glia cells from a permanent cell line originating from the brain cortex of rat embryos are most sensitive when treated with cyplasin. Addition of 0.5 nM
cyplasin is sufficient to induce cell death (arrows ) . Rat kangaroo PtK cells require 2 nM cyplasin to exhibit the morphology of dying cells. Recombinant cyplasin - L–
EGFP: Standard extracts of recombinant cyplasin - L–EGFP (100 l / 500 l medium) show, in parallel cultures, essentially identical and graded cytotoxic effects
( arrows ) . Bar, 10 m.
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actin is found in the cytoplasm, with the exception of the
cortical area (Figure 9d  f , arrows ) .
Evaluation of the Bioactive Recombinant
Cyplasin-L–EGFP
A thorough side-by-side comparison of the biochemically
isolated genuine cyplasin and the recombinant cyplasin-L–
EGFP version meets the problem that the recombinant is, at
present, only available on the level of enriched extracts.
Although an exact quantitation is missing, so far, it is evident
that the cyplasin-L–EGFP extracted from stably transfected
SF9 cells exhibits cytotoxic activity, which is very similar to
that induced by the biochemically isolated genuine cyplasin.
Figure 5 presents side by side the effects of genuine cyplasin
and recombinant cyplasin-L–EGFP on four different cell
lines with established different sensitivities to genuine
cyplasin. Using constant amounts of extracts from cypla-
sin-L–EGFP–expressing SF9 cells, it is obvious that HSFs
are relatively insensitive to recombinant cyplasin-L–EGFP,
which holds true also for the biochemically isolated genuine
cyplasin. These cells only show a slight initial retraction and a
weak tendency to shrink when treated either with genuine
cyplasin (50 nM) or with the standard extracts containing the
cyplasin-L–EGFP. Finally, they recover and continue to
proliferate. Death of HSF cells is only observed at cyplasin
concentrations in the order of 100 nM. In contrast, cells
derived from a biopsy of a human melanoma exhibit
significantly higher sensitivity when incubated with genuine
cyplasin (1 nM) and with the standard extract. Melanoma
cells treated either with the genuine cyplasin or with the
recombinant cyplasin-L–EGFP show the typical cyplasin-
induced retractions, the formation of vacuoles, and finally cell
death. Other panels of this figure show glia cells from an
established cell line derived from rat embryo cortices. These
cells exhibit the highest cyplasin sensitivity of all cells studied
so far. The typical cyplasin effect is observed at a
concentration that is as low as 0.2 nM, and complete cell
death is observed within a 5-hour observation period. The
cells of the kangaroo rat line PtK are irreversibly damaged
within 24 hours by incubation with 2 nM genuine cyplasin. A
similar effect is observed after treatment with the standard
extract. Prominent plasma vacuolisation and membrane
changes are induced in these cells by genuine cyplasin as
well as by recombinant cyplasin-L–EGFP.
Summarizing, these results show that the molecular
cloning approach released a cDNA encoding a factor
exhibiting cytotoxic activity similar to that detected in the
secreted mucus of A. punctata, and that the cytotoxic effect
of the recombinant protein is not obliterated by its fusion to
EGFP.
Target Site for Cyplasin Action
The exact mechanisms behind the cytotoxic effects of
cyplasin and recombinant cyplasin are not yet elaborated.
However, it is unlikely that the cells take up a protein of this
Figure 8. Anaphase progress of a PtK cell present in a culture treated for
1 hour with 2 nM genuine cyplasin. From upper left to lower right: No
interference is observed with the process of anaphase, which is
terminating in an apparently normal cytokinesis. After entering interphase,
this cell showed the typical cyplasin - induced changes in morphology. Bar,
10 m.
Figure 7. Apoptotic cell death induced by staurosporine and cell death
induced by genuine cyplasin. PtK cells were treated with 10 nM cyplasin for 5
hours ( upper panel ) , or with 1 g /ml staurosporin for 3 hours ( lower panel ) .
The cells were stained with a mixture of FITC - labeled Annexin V and
propidium iodide as described elsewhere in detail [ 8 ] . The FITC–Annexin V
staining shows the characteristic translocation of phosphatidylserine from the
inner to the outer side of the plasma membrane. No FITC–Annexin V staining
is found in cyplasin - treated cells that show the characteristic cyplasin -
induced morphological changes. Neither staurosporine nor cyplasin perme-
abilizes the cells, which is revealed by missing propidium iodide staining of
nuclei. Bar, 10 m.
Figure 6. Dose– response curve of cyplasin for various cell lines. Glia cells
are the cells most sensitive to cyplasin. Less than 1 nM cyplasin suffices to kill
the majority of them. Primary human melanoma cells and PtK cells show also
a high sensitivity to cyplasin, whereas HSFs are much more tolerant; only a
dose as high as 100 nM cyplasin will kill these cells.
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size with the consequence of exerting negative intracellular
influence. Long- term observations of cyplasin- treated cells
indicate that the first signs of cytotoxic action occur at the
outer cellular membrane, at a time when the internal cell
morphology shows no anomalies. This observation suggests
that cyplasin docking to the outer cellular membrane
represents the trigger for a still unknown cascade of events
that finally leads to cell death. This view is also in agreement
with other observations. Mammalian cells transfected with
expression constructs specifying cyplasin-L or EGFP-
tagged cyplasin-L initially survive and they are able to
produce the cytotoxic factor. However, they begin to exhibit
the changed morphology as soon as the cytotoxic factor
becomes detectable in the spent medium. This suggests that
extracellular cyplasin is cytotoxic, whereas intracellular
cyplasin is rather nontoxic.
Such a hypothesis was confirmed recently when, after
removal of the secretion signal in the cyplasin sequence,
mammalian cells were transfected with the modified con-
struct. These cells expressed cyplasin, but continued to
proliferate. Only upon homogenisation and subsequent
purification did the cytotoxicity of cyplasin become apparent,
killing now even the producing cells (Petzelt et al.,
unpublished) .
Absence of In Vivo Toxicity of Cyplasin
In order to test if cyplasin showed cytotoxic effects also in
vivo, either genuine or recombinant cyplasin was injected
into three groups of mice. Group 1 consisted of 12 DBA2
mice, which were injected with a high concentration of
cyplasin into the tail vein. The concentration used exceeded
by far the concentration found to be toxic in vitro. Never-
theless, all mice survived, at least up to 4 weeks. The same
result was obtained when in a second group 12 DBA2 mice
were injected subcutaneously under identical conditions.
They survived and no negative effects were found during the
observation period. Finally, a third group (six mice) was
injected into the tail vein using the recombinant cyplasin.
Again all mice survived.
Discussion
The results support previous suggestions pointing to
cytotoxic substances of high molecular weight that are
produced and secreted by Aplysia species [5,6 ] . Protein
fractions from the secreted mucus of A. punctata show
cytotoxic, and finally killing, activity when added to cells that
grow independently of proliferation-controlling activities,
e.g., in culture. One of these factors has been charac-
Figure 9. Effect of cyplasin on the actin cytoskeleton of human primary melanoma cells. Cyplasin ( 10 nM) causes a fast depolymerization of actin fibers, with the
exception of the cortical area where f - actin staining persists (arrows ) . ( a ) Untreated control; ( b ) 30 -minute cyplasin incubation; ( c ) 60 -minute cyplasin
incubation; ( d ) 90 -minute cyplasin incubation; ( e ) 120 -minute cyplasin incubation; ( f ) 180 -minute cyplasin incubation. Bar, 10 m.
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terized on the peptide sequence level and it has been
termed cyplasin. Interestingly, cyplasin shows a graded
cytoxicity on cells in culture. It is highly cytotoxic to
established cell lines, as shown for the glia cell line and
PtK cells, as well as to many primary tumor cells, such as
the human melanoma tested. HSFs show a significantly
higher tolerance. Because other tumor cells tested are also
highly sensitive (not shown), it appears that cyplasin is
especially cytotoxic to established cell lines and to primary
tumor cells. The different response of primary human
fibroblasts is probably due to the fact that these cells
cannot be considered as tumor cells although growing
autonomously [18] . Accordingly, cyplasin might be useful
for the specific elimination of nondesired cells in an
organism, such as tumor cells.
Such a view is supported by preliminary in vivo
experiments. In no case was a toxic effect of the injected
cyplasin found when injected in normal mice, even when
high concentrations of cyplasin were used. Presently,
experiments with tumor-bearing animals are in progress
to increase information on such preferential tumor cell
cytotoxicity.
The natural source for cyplasin is limited; hence, its
recombinant production appears to be a prerequisite for its
potential application as an anticancer drug. In a first step, we
searched for a cDNA, which could be considered to encode
the protein with an apparent molecular mass of 56 kDa,
which had been isolated by the bioassay-guided fractiona-
tion procedure. Using a subsequence of this protein as probe
and conventional PCR and cDNA cloning techniques, we
found that more than one A. punctata transcript comprises
the subsequence used as specific probe. Two cDNA
encoding polypeptides with diverging carboxy- termini could
be identified on the sequence level. Moreover, individual
cDNA clones showed slightly diverging nucleotide sequen-
ces when PCR products were cloned, which were prepared
on the basis of complete A. punctata cDNA library template
and primer pairs fitting the coding regions of the cDNA
identified in the first step. Actually, all individual clones
investigated so far showed slightly different nucleotide
sequences with the consequence of one or more amino acid
exchanges in the corresponding polypeptide. It is highly
unlikely that all these transcripts originate from different
genes in A. punctata. Posttranslational processes like
alternative splicing, differential polyadenylation, and RNA
editing could result in transcripts encoding the different
polypeptides.
At this stage, it is unknown whether the different
polypeptides identified at the transcript level exhibit all
identical functions. In this situation, it appeared worthwhile
to select only one cDNA species (encoding the protein
termed cyplasin-L) and to investigate whether this
sequence could encode a cytotoxic protein. The recombi-
nant polypeptide produced in E. coli was found to be
biologically inactive. However, eukaryotic cells transfected
with constructs expressing this selected cDNA or this cDNA
in fusion with the EGFP-encoding nucleotide sequence
produced a cytotoxic factor that was not present in
nontransfected cells nor in cyplasin-S–transfected cells.
Insect cells (SF9) transfected with pIZ-driven expression
constructs became especially useful. In this case, stably
transfected cell lines could be established, which permitted
the preparation of biologically active EGFP-tagged cypla-
sin-L in quantities sufficient to compare the biological
activity of the recombinant protein with the material that can
be biochemically isolated from the secreted mucus of A.
punctata. The very similar morphological effects achieved
by the biochemical isolate and by the recombinantly
expressed protein suggest that the selected cDNA is a
valid clone and that it encodes a protein presenting the
cytotoxic principle of the genuine cyplasin of A. punctata.
With the availability of bioactive recombinant cyplasin, it is
now possible to evaluate its potential antitumor therapeutic
value.
Further studies should reveal whether the cloned cDNA
specifies the only cytotoxic protein among the slightly
different transcripts mentioned above or whether other
transcripts encode proteins that possess equal or even
greater cytotoxic activity.
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